



**GENERAL ORDERING FORM**

Client

**Account #**

**Name:**

Address:

Phone:

Patient

Last, First M

male  female

DOB \_\_\_\_\_ SS# \_\_\_\_\_

Address \_\_\_\_\_

Patient ID

Facility ID

Other ID

**ORDERING PHYSICIAN**

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Physician

Billing

Client  Insurance/Patient (Please Attach Copy Insurance Info)

Insurance Company \_\_\_\_\_

Policy # \_\_\_\_\_ Group # \_\_\_\_\_

Insurance Address \_\_\_\_\_

Specimen

Collection Date/Time \_\_\_\_\_  am  pm

Blood  Bone Marrow Aspirate  Core Biopsy  Clot

Tissue, specify site \_\_\_\_\_

Paraffin-embedded\* Specimen # \_\_\_\_\_ Block # \_\_\_\_\_  Slides

\*Please provide copy of Surgical Pathology Report

\*Permission to exhaust block  Yes  No  Please call to confirm

FNA, specify site \_\_\_\_\_

Fluids:  BAL  CSF  Pleural fluid

ThinPrep®  SurePath™  Aptima® Swab  Cervical Swab  Urine

Plasma  Serum  Sputum  Aptima® Urine  Swab \_\_\_\_\_

Other specimen, specify site \_\_\_\_\_

**Clinical Indication** (Specify ICD-9 codes and diagnosis **REQUIRED**)

**Comments/Patient History/Special Request**

**INFECTIOUS DISEASES**

- CT** Chlamydia trachomatis, qualitative
- NG** Neisseria gonorrhoeae, qualitative
- CTNG** Chlamydia/gonorrhoeae, qualitative
- HCV Q** Hepatitis C virus, quantitative
- HIV Q** Human immunodeficiency virus, quantitative
- HCV G** genotyping
- HPV** Human papillomavirus, low/high risk, HC II
- HPV HR** high risk only, HC II
- HPV G** genotyping
- HSV** Herpes simplex virus 1 & 2, qualitative
- HSV1** HSV 1, qualitative
- HSV2** HSV 2, qualitative

**MOLECULAR GENETICS**

- CF** Cystic Fibrosis (32 mutation panel)
- CF-5T** CF intron 8 5T/7T/9T
- F2PRO** Factor II prothrombin G20210A
- FVLEI** Factor V Leiden R506Q
- MTHFR C677T** and A1298C mutation
- MTHFR 677** mutation
- PAI** Plasminogen activator inhibitor type I 4G/5G
- WARF** Warfarin Sensitivity

**PATHOLOGY**

- BMPE** Bone Marrow Pathology Evaluation
- PBSP** Peripheral Blood Smear Evaluation
- SPP** Surgical Pathology Professional Evaluation
- SPC** Surgical Pathology Consultation

**CYTOGENETICS**

- CYTO BM** marrow
- CYTO UPB** blood
- CYTO ST** solid tumor
- CYTO TC** product of conception, skin biopsy
- CYTO PB** constitutional blood

**CELL SEARCH**

**Circulating Tumor Cell Detection**

- CELLSEARCH** check one below
- breast  colon  prostate

**FLOW CYTOMETRY**

- FLOW** Myeloid/Lymphoid Markers (leukemia/myeloma/non-Hodgkin lymphoma)  
For limited/targeted markers, please check:
  - Lymphoid markers **only**
  - B cell/plasma cell markers **only** (i.e. monoclonal gammopathy)
  - Residual disease (please specify disease)
  - Other (please specify) \_\_\_\_\_
- For reflex testing if FLOW positive for B-CLL clone
  - FLOW ZAP70** or  **F CLL** (FISH)
- FLOW PNH** Paroxysmal nocturnal hemoglobinuria (CD55,CD59,FLAER)
- FLOW BAL** Bronchoalveolar lavage (CD4:CD8)
- FLOW LAD** Leukocyte adhesion (CD11a,CD11b,CD11c,CD18)
- FLOW ZAP70** ZAP-70
- FLOW CD4** T cell subsets (CD3,CD4,CD8,CD4:CD8)
- FLOW EX** Lymphocyte analysis (T cell subsets, CD19,CD56)
- PLOIDY** Cell cycle analysis; DNA Ploidy and S Phase

**MOLECULAR ONCOLOGY**

- ABL G** kinase Gleevec® resistance
- BRAF** V600 mutation, EGFR inhibitor/response
- KRAS** mutation, EGFR inhibitor/response
  - reflex** to **BRAF** if KRAS normal
- P AML** mutation profile (**FLT3** and **NPM1**)
  - reflex** to **CEBPA** testing if FLT3 and NPM1 negative
- P BCELL** Ig heavy chain gene rearrangement
  - reflex** to **P IGH** kappa light chain if IGH negative
- P BCL2** t(14;18) gene rearrangement
- P JAK2** V617F Ph negative chronic MPD
- P TCR** T cell receptor gamma gene rearrangement
- UGT1A1** genotyping **Camptosar™** toxicity  
Quantitative PCR and minimal residual disease testing
  - P BCR ABL** initial diagnostic workup
  - P BCR ABLm** disease monitoring
  - P PML RARA** initial diagnostic workup
  - P PML RARAm** disease monitoring

**IHC  TC Technical  Global**

- I ER**  **I PR**  **I HER2**  **I KI67**  
 **reflex** to F HER2 if I HER2 is  1+  2+  3+
- I AE1/AE3** Cytokeratin cocktail, PAN
- I CK7** Cytokeratin 7, 54kD
- I CK20** Cytokeratin 20
- I MSI** Microsatellite instability - MLH1, MSH2, MSH6, PMS2
- Other** \_\_\_\_\_
- Other** \_\_\_\_\_

**FISH**

**Profiles**

- F AALL Adult:** t(9;22), 11q23, t(12;21)
- F CLL** p53, 11q22, 13q14/13q34, +12, 6q-
- F MDS** -5/5q-, -7/7q-, +8, 20q-
- F MPD** t(9;22), +8, 13q14, 20q-  
 **reflex** to **JAK-2** if t(9;22) negative
- F MM** +5/+9/+15, 13q14, p53, 14q32  
includes reflex **F FGFR3** t(4;14), t(11;14),  
**F IGH MAF** t(14;16) if IGH rearranged
- F PALL Pediatric:** t(9;22), +4, +10, +17, 11q23, t(12;21)

**Common Individual Probes**

- F 4Q12** FIP1L1/PDGFR, CHIC2
- F ALK** 2p23
- F AML ETO** t(8;21)
- F API MALT** t(11;18)
- F ATM** 11q22
- F BCL1** t(11;14)
- F BCL2** t(14;18)
- F BCL6** 3q27
- F BCR ABL** t(9;22)  
 **reflex** to **JAK-2** if negative
- F CBFB** t(16;16), inv(16)
- F CMYC** 8q24
- F D1314** 13q14
- F D20** 20q-
- F EGFR** HER1/erb-B1
- F EWSR1** Ewing Sarcoma 22q12
- F FGFR3** t(4;14)
- F GLI** Oligodendroglioma 1p36-/19q13-
- F HER2** Her2/neu, breast cancer
- F IGH** 14q32
- F IGH MAF** t(14;16)
- F IGH MALT** t(14;18)
- F IGH MYC** t(8;14)
- F MALT** 18q21
- F MLL** 11q23
- F N MYC** 2p24
- F P53** 17p13
- F PML RARA** t(15;17)
- F PTEN** 10q23-
- F SYT** 18q11 synovial sarcoma
- F SRY** X/Y sex-mismatch
- F TEL AML1** t(12;21)
- F URO** +3, +7, +17, 9p21- bladder cancer
- Other** \_\_\_\_\_